These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1021 related items for PubMed ID: 22141732

  • 1. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY.
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [Abstract] [Full Text] [Related]

  • 2. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D.
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [Abstract] [Full Text] [Related]

  • 3. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
    Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V.
    J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
    [Abstract] [Full Text] [Related]

  • 4. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Longo F, Mansueto G, Lapadula V, De Sanctis R, Quadrini S, Grande R, Gori B, Altavilla A, D'Antoni I, Del Signore E, Stumbo L, De Luca C, Cimadon B, Cortesi E, Gamucci T, Di Seri M.
    Support Care Cancer; 2011 Aug; 19(8):1159-64. PubMed ID: 20552375
    [Abstract] [Full Text] [Related]

  • 5. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
    Miura S, Watanabe S, Sato K, Makino M, Kobayashi O, Miyao H, Iwashima A, Okajima M, Tanaka J, Tanaka H, Kagamu H, Yokoyama A, Narita I, Yoshizawa H.
    Support Care Cancer; 2013 Sep; 21(9):2575-81. PubMed ID: 23644992
    [Abstract] [Full Text] [Related]

  • 6. Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy.
    Yang CK, Wu CE, Liaw CC.
    Biomed J; 2016 Feb; 39(1):60-6. PubMed ID: 27105599
    [Abstract] [Full Text] [Related]

  • 7. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
    Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH.
    J Clin Oncol; 2012 Nov 10; 30(32):3998-4003. PubMed ID: 22915652
    [Abstract] [Full Text] [Related]

  • 8. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Horgan KJ.
    Eur J Cancer; 2004 Feb 10; 40(3):403-10. PubMed ID: 14746859
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H, Yamamoto N, Shirai T, Nishida H, Hayashi K, Tanzawa Y, Takeuchi A, Igarashi K, Inatani H, Shimozaki S, Kato T, Aoki Y, Higuchi T, Tsuchiya H.
    Cancer Med; 2015 Mar 10; 4(3):333-41. PubMed ID: 25533447
    [Abstract] [Full Text] [Related]

  • 10. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
    Kitamura H, Takahashi A, Hotta H, Kato R, Kunishima Y, Takei F, Horita H, Masumori N, Sapporo Medical University Urologic Oncology Consortium.
    Int J Urol; 2015 Oct 10; 22(10):911-4. PubMed ID: 26087891
    [Abstract] [Full Text] [Related]

  • 11. Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy.
    Hamada S, Hinotsu S, Kawai K, Yamada S, Narita S, Kamba T, Nishiyama H, Arai Y, Habuchi T, Ogawa O, Kawakami K.
    Support Care Cancer; 2014 Aug 10; 22(8):2161-6. PubMed ID: 24652048
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
    Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M.
    Support Care Cancer; 2009 May 10; 17(5):589-94. PubMed ID: 19037667
    [Abstract] [Full Text] [Related]

  • 13. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA.
    J Support Oncol; 2006 Oct 10; 4(9):467-71. PubMed ID: 17080735
    [Abstract] [Full Text] [Related]

  • 14. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
    de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ.
    J Clin Oncol; 2003 Nov 15; 21(22):4105-11. PubMed ID: 14559891
    [Abstract] [Full Text] [Related]

  • 15. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S.
    Lancet Oncol; 2009 Feb 15; 10(2):115-24. PubMed ID: 19135415
    [Abstract] [Full Text] [Related]

  • 16. Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
    Roila F, Ruggeri B, Ballatori E, Fatigoni S, Caserta C, Licitra L, Mirabile A, Ionta MT, Massidda B, Cavanna L, Palladino MA, Tocci A, Fava S, Colantonio I, Angelelli L, Ciuffreda L, Fasola G, Zerilli F.
    Ann Oncol; 2015 Jun 15; 26(6):1248-1253. PubMed ID: 25743855
    [Abstract] [Full Text] [Related]

  • 17. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM.
    J Support Oncol; 2003 Jun 15; 1(2):89-103. PubMed ID: 15352652
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Oyama K, Fushida S, Kaji M, Takeda T, Yabushita K, Nezuka H, Kinami S, Kadoya N, Takai Y, Tsukioka Y, Ohyama S, Tsuji K, Tsukada T, Kinoshita J, Fujimura T, Ohta T.
    Int J Clin Oncol; 2016 Jun 15; 21(3):483-90. PubMed ID: 26507140
    [Abstract] [Full Text] [Related]

  • 19. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
    Nakashima K, Murakami H, Yokoyama K, Omori S, Wakuda K, Ono A, Kenmotsu H, Naito T, Nishiyama F, Kikugawa M, Kaneko M, Iwamoto Y, Koizumi S, Mori K, Isobe T, Takahashi T.
    Jpn J Clin Oncol; 2017 Sep 01; 47(9):840-843. PubMed ID: 28633504
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial.
    Takeshima N, Matoda M, Abe M, Hirashima Y, Kai K, Nasu K, Takano M, Furuya K, Sato S, Itamochi H, Tsubamoto H, Hasegawa K, Terao K, Otsuki T, Kuritani K, Ito K.
    Support Care Cancer; 2014 Nov 01; 22(11):2891-8. PubMed ID: 24825735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.